171 related articles for article (PubMed ID: 36759998)
21. Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma.
Kuzuya T; Kawabe N; Hashimoto S; Miyahara R; Sawaki A; Nakano T; Nakaoka K; Tanaka H; Miyachi Y; Mii A; Kamejima S; Takahara T; Kato Y; Sugioka A; Hirooka Y
Oncology; 2022; 100(1):12-21. PubMed ID: 34731863
[TBL] [Abstract][Full Text] [Related]
22. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
[TBL] [Abstract][Full Text] [Related]
23. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.
Komatsu S; Fujishima Y; Kido M; Kuramitsu K; Goto T; Yanagimoto H; Toyama H; Fukumoto T
BMC Gastroenterol; 2021 Dec; 21(1):470. PubMed ID: 34911458
[TBL] [Abstract][Full Text] [Related]
24. Evans' syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma.
Fukushima M; Tajima K; Sasaki R; Nakao Y; Takahashi K; Ozawa E; Miuma S; Kato T; Miyaaki H; Nakao K
Clin J Gastroenterol; 2023 Jun; 16(3):402-406. PubMed ID: 36746879
[TBL] [Abstract][Full Text] [Related]
25. Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report.
Uchida K; Ozono Y; Uchiyama N; Hatada H; Nakamura K; Komaki Y; Iwakiri H; Hasuike S; Nagata K; Sato Y; Kawakami H
Medicine (Baltimore); 2022 Sep; 101(35):e30486. PubMed ID: 36107543
[TBL] [Abstract][Full Text] [Related]
26. Complete Metabolic Response by 18 F-FDG PET/CT to Atezolizumab Plus Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.
Uchida Y; Yoh T; Fukui A; Takai A; Hatano E
Clin Nucl Med; 2023 May; 48(5):417-419. PubMed ID: 36727879
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
Xin Y; Cao F; Yang H; Zhang X; Chen Y; Cao X; Zhou X; Li X; Zhou J
Front Immunol; 2022; 13():929141. PubMed ID: 35990634
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
29. [Retroperitoneal metastasis of hepatocellular carcinoma - a case report].
Kobayashi S; Ueno M; Ohkawa S; Kameda R; Miyakawa K; Tamura S; Kanazawa A; Yamamoto N; Morinaga S
Gan To Kagaku Ryoho; 2011 Mar; 38(3):465-8. PubMed ID: 21403456
[TBL] [Abstract][Full Text] [Related]
30. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?
Fernandez-Sevilla E; Allard MA; Selten J; Golse N; Vibert E; Sa Cunha A; Cherqui D; Castaing D; Adam R
Liver Transpl; 2017 Apr; 23(4):440-447. PubMed ID: 28187493
[TBL] [Abstract][Full Text] [Related]
31. Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection.
Wada H; Nagano H; Noda T; Damdinsuren B; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Sakon M; Wakasa K; Monden M
J Gastroenterol; 2007 Jun; 42(6):501-6. PubMed ID: 17671767
[TBL] [Abstract][Full Text] [Related]
32. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
Hayakawa Y; Tsuchiya K; Kurosaki M; Yasui Y; Kaneko S; Tanaka Y; Ishido S; Inada K; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Izumi N
Invest New Drugs; 2022 Apr; 40(2):392-402. PubMed ID: 34586531
[TBL] [Abstract][Full Text] [Related]
33. A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events.
Hayashi H; Sawada K; Hasebe T; Nakajima S; Sawada J; Takiyama Y; Takiyama Y; Okumura T; Fujiya M
Intern Med; 2022 Dec; 61(23):3497-3502. PubMed ID: 35491133
[TBL] [Abstract][Full Text] [Related]
34. Repeated resection for extrahepatic recurrences after hepatectomy for ruptured hepatocellular carcinoma.
Kaido T; Arii S; Shiota M; Imamura M
J Hepatobiliary Pancreat Surg; 2004; 11(2):149-52. PubMed ID: 15127281
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab.
Shigefuku R; Yoshikawa K; Tsukimoto M; Owa H; Tamai Y; Tameda M; Ogura S; Sugimoto R; Tanaka H; Eguchi A; Sugimoto K; Hasegawa H; Iwasa M; Nakagawa H
Intern Med; 2023 Feb; 62(4):539-543. PubMed ID: 35732454
[TBL] [Abstract][Full Text] [Related]
36. A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment.
Cho Y; Kim BH; Kim TH; Koh YH; Park JW
J Liver Cancer; 2023 Mar; 23(1):206-212. PubMed ID: 37384027
[TBL] [Abstract][Full Text] [Related]
37. [Minimally Invasive Conversion Hepatectomy for Advanced Hepatocellular Carcinoma].
Sakai H; Goto Y; Shimose S; Niizeki T; Kawaguchi T; Akiba J; Yano H; Akagi Y; Fujita F; Hisaka T
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1572-1574. PubMed ID: 38303345
[TBL] [Abstract][Full Text] [Related]
38. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
Hack SP; Spahn J; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Yopp A; Chow P; Qin S
Future Oncol; 2020 May; 16(15):975-989. PubMed ID: 32352320
[TBL] [Abstract][Full Text] [Related]
39. Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma.
Tsilimigras DI; Moris D
J BUON; 2021; 26(2):637. PubMed ID: 34077021
[No Abstract] [Full Text] [Related]
40. Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection.
Ochiai T; Ikoma H; Okamoto K; Kokuba Y; Sonoyama T; Otsuji E
World J Surg; 2012 Jan; 36(1):136-43. PubMed ID: 22051887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
